{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:47:06Z","timestamp":1768834026901,"version":"3.49.0"},"reference-count":53,"publisher":"Impact Journals, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,2,2]]},"DOI":"10.18632\/oncotarget.6685","type":"journal-article","created":{"date-parts":[[2015,12,31]],"date-time":"2015-12-31T21:26:44Z","timestamp":1451597204000},"page":"5507-5520","source":"Crossref","is-referenced-by-count":24,"title":["CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia"],"prefix":"10.18632","volume":"7","author":[{"given":"Arnau","family":"Montraveta","sequence":"first","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriong","family":"Lee-Verg\u00e9s","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocabed","family":"Rold\u00e1n","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Cabezas","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillem","family":"Clot","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda","family":"Pinyol","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00edlvia","family":"Xargay-Torrent","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"Rosich","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Arimany-Nard\u00ed","sequence":"additional","affiliation":[{"name":"Departament de Bioqu\u00edmica i Biologia Molecular, Institut de Biomedicina, Universitat de Barcelona and Oncology Program, CIBEREHD, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Aymerich","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neus","family":"Villamor","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"P\u00e9rez-Gal\u00e1n","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00ebl","family":"Rou\u00e9","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00e7al","family":"Pastor-Anglada","sequence":"additional","affiliation":[{"name":"Departament de Bioqu\u00edmica i Biologia Molecular, Institut de Biomedicina, Universitat de Barcelona and Oncology Program, CIBEREHD, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u00edas","family":"Campo","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"L\u00f3pez-Guerra","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2015,12,19]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1172\/JCI64101","article-title":"Molecular pathogenesis of chronic lymphocytic leukemia","volume":"122","author":"la-Favera","year":"2012","journal-title":"J Clin Invest"},{"key":"2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Stilgenbauer","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Juan","year":"2011","journal-title":"Nature"},{"key":"4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Navarro","year":"2012","journal-title":"Nat Genet"},{"key":"5","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Fernandes","year":"2011","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/gm451","article-title":"Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics","volume":"5","author":"Wu","year":"2013","journal-title":"Genome Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Belver","year":"2015","journal-title":"Nature"},{"key":"8","doi-asserted-by":"publisher","first-page":"22734","DOI":"10.18632\/oncotarget.4212","article-title":"The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia","volume":"6","author":"Colomer","year":"2015","journal-title":"Oncotarget"},{"key":"9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/leu.2014.143","article-title":"The gamma-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells","volume":"29","author":"Colomer","year":"2015","journal-title":"Leukemia"},{"key":"10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2015-04-585067","article-title":"Initial treatment of CLL: integrating biology and functional status","volume":"126","author":"O'Brien","year":"2015","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2014.55.8262","article-title":"Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician","volume":"32","author":"Flynn","year":"2014","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Buhler","year":"2012","journal-title":"J Clin Oncol"},{"key":"13","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Elter","year":"2011","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12000","article-title":"Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial","volume":"159","author":"Huguet","year":"2012","journal-title":"Br J Haematol"},{"key":"15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/2040620713478629","article-title":"Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study","volume":"4","author":"Kennealey","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"16","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1182\/blood-2014-12-613570","article-title":"Obinutuzumab plus fludarabine\/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial","volume":"125","author":"Kipps","year":"2015","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/leu.2013.334","article-title":"Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial","volume":"28","author":"Storti","year":"2014","journal-title":"Leukemia"},{"key":"18","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2014-09-585869","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia","volume":"125","author":"O'Brien","year":"2015","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggest ABT-199 as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Gandhi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/leu.2011.364","article-title":"Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells","volume":"26","author":"Colomer","year":"2012","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Blum","year":"2015","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3324\/haematol.2013.088849","article-title":"The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt\/FoxO3a\/Bim axis in chronic lymphocytic leukemia cells","volume":"98","author":"Colomer","year":"2013","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"23","first-page":"S12","article-title":"Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity","volume":"48","author":"Hartley","year":"2011","journal-title":"Semin Hematol"},{"key":"24","first-page":"1","article-title":"Bendamustine: mechanism of action and clinical data","volume":"9","author":"Leoni","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"25","doi-asserted-by":"crossref","first-page":"F330","DOI":"10.1152\/ajprenal.00467.2014","article-title":"Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake","volume":"308","author":"Burckhardt","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/tpj.2014.77","article-title":"Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells","volume":"15","author":"Pastor-Anglada","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"27","first-page":"687","article-title":"Highly purified CD38+ and","volume":"21","author":"Fegan","year":"2007","journal-title":"Leukemia"},{"key":"28","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2404363","article-title":"Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status","volume":"20","author":"Durig","year":"2006","journal-title":"Leukemia"},{"key":"29","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","article-title":"Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance","volume":"114","author":"Gandhi","year":"2009","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Kipps","year":"2000","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"McCoy","year":"2011","journal-title":"Blood"},{"key":"32","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood-2013-12-541433","article-title":"Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells","volume":"123","author":"Gandhi","year":"2014","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1182\/blood-2010-11-315705","article-title":"The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia","volume":"117","author":"Johnson","year":"2011","journal-title":"Blood"},{"key":"34","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","article-title":"Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL","volume":"123","author":"Wiestner","year":"2014","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2010.32.3865","article-title":"Update on therapy of chronic lymphocytic leukemia","volume":"29","author":"O'Brien","year":"2011","journal-title":"J Clin Oncol"},{"key":"36","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1158\/1078-0432.CCR-08-0388","article-title":"Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling","volume":"14","author":"Colomer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Niemeyer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"38","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/sj.leu.2402651","article-title":"evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia","volume":"16","author":"Karakas","year":"2002","journal-title":"Leukemia"},{"key":"39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3109\/08923979909007126","article-title":"CD69 and regulation of the immune function","volume":"21","author":"Betz-Corradin","year":"1999","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0167-5699(94)90193-7","article-title":"The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells","volume":"15","author":"Santoni","year":"1994","journal-title":"Immunol Today"},{"key":"41","first-page":"497056","article-title":"CD69 Is the Crucial Regulator of Intestinal Inflammation: A New Target Molecule for IBD Treatment?","volume":"2015","author":"Niess","year":"2015","journal-title":"J Immunol Res"},{"key":"42","first-page":"995","article-title":"CD69 expression in B-cell chronic lymphocytic leukemia: a new prognostic marker?","volume":"86","author":"Pistolese","year":"2001","journal-title":"Haematologica"},{"key":"43","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2011.052829","article-title":"CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study","volume":"97","author":"Simotti","year":"2012","journal-title":"Haematologica"},{"key":"44","doi-asserted-by":"publisher","first-page":"7632","DOI":"10.18632\/oncotarget.2939","article-title":"Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating","volume":"6","author":"Crespo","year":"2015","journal-title":"Oncotarget"},{"key":"45","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2141.2012.09191.x","article-title":"Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells","volume":"158","author":"Pepper","year":"2012","journal-title":"Br J Haematol"},{"key":"46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2217\/fon.14.119","article-title":"The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed\/refractory chronic lymphocytic leukemia","volume":"11","author":"Howes","year":"2015","journal-title":"Future Oncol"},{"key":"47","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity","volume":"123","author":"Byrd","year":"2014","journal-title":"Blood"},{"key":"48","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V124.21.3343.3343","article-title":"Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG) in Combination with Bendamustine (B), Bendamustine\/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil\/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","volume":"124","author":"Viggiano","year":"2014","journal-title":"Blood"},{"key":"49","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood.V124.21.3063.3063","article-title":"Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I\/II Results","volume":"124","author":"Holes","year":"2014","journal-title":"Blood"},{"key":"50","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00280-015-2727-6","article-title":"Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites","volume":"75","author":"Chovan","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"51","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Jaffe","year":"2011","journal-title":"Blood"},{"key":"52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2404457","article-title":"ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia","volume":"21","author":"Rosenquist","year":"2007","journal-title":"Leukemia"},{"key":"53","doi-asserted-by":"publisher","first-page":"726","DOI":"10.18632\/oncotarget.1455","article-title":"Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab inandmodels of mantle cell lymphoma","volume":"5","author":"Colomer","year":"2014","journal-title":"Oncotarget"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T17:11:11Z","timestamp":1589217071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,19]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,2,2]]}},"alternative-id":["6685","26701728"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.6685","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,19]]}}}